HUTCHMED (China) Limited (AIM: HCM)
Market Cap | 2.14B |
Revenue (ttm) | 483.31M |
Net Income (ttm) | -33.21M |
Shares Out | 854.55M |
EPS (ttm) | -0.04 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 20,590 |
Open | n/a |
Previous Close | 261.00 |
Day's Range | 248.90 - 257.00 |
52-Week Range | 190.40 - 353.00 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Nov 13, 2024 |
About HUTCHMED (China)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, an... [Read more]
News
![](https://cdn.snapi.dev/images/v1/g/g/press9-2631815.jpg)
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several...
HUTCHMED pulls regulatory submission for Takeda-partnered cancer drug in China
HUTCHMED pulls regulatory submission for Takeda-partnered cancer drug in China
![](https://cdn.snapi.dev/images/v1/y/i/press9-2617364.jpg)
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has voluntarily withdrawn its...
![](https://cdn.snapi.dev/images/v1/z/n/press17-2600554.jpg)
HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a physician expert ...
![](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1647065686/image_1647065686.jpg?io=getty-c-w1536)
Hutchmed Growing Sales By 64% In H1 2024
The approval of the colon cancer drug FRUZAQLA has boosted sales for HUTCHMED, leading to a nearly 20% increase in share price. Read more on HCM stock here.
![](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1647065686/image_1647065686.jpg?io=getty-c-w1536)
Hutchmed Growing Sales By 64% In H1 2024
The approval of the colon cancer drug FRUZAQLA has boosted sales for HUTCHMED, leading to a nearly 20% increase in share price. Read more on HCM stock here.
![](https://cdn.snapi.dev/images/v1/r/i/transcript39-2558429.jpg)
HUTCHMED (China) Limited (HCM) Q2 2024 Earnings Call Transcript
HUTCHMED (China) Limited (NASDAQ:HCM) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants David Ng - Head:Investor Relations Wei-Guo Su - Chief Executive Officer & Chief Sc...
![](https://cdn.snapi.dev/images/v1/0/t/press13-2509462.jpg)
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”)...
![](https://cdn.snapi.dev/images/v1/0/p/conf10-2496750.jpg)
HUTCHMED to Announce 2024 Half-Year Financial Results
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six mon...
![](https://cdn.snapi.dev/images/v1/y/t/conf4-2492266.jpg)
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
— HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 — — HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 —
![](https://cdn.snapi.dev/images/v1/1/6/press8-2490894.jpg)
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial —
![](https://cdn.snapi.dev/images/v1/a/a/press12-2481240.jpg)
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior...
![](https://cdn.snapi.dev/images/v1/8/v/press10-2467549.jpg)
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical ...
![](https://cdn.snapi.dev/images/v1/s/v/press17-2458206.jpg)
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024 Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024
![](https://cdn.snapi.dev/images/v1/4/b/press17-2446712.jpg)
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from se...
![](https://cdn.snapi.dev/images/v1/g/r/press19-2437148.jpg)
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces:-
![](https://cdn.snapi.dev/images/v1/d/w/press2-2436401.jpg)
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ...
![](https://cdn.snapi.dev/images/v1/w/r/press16-2428462.jpg)
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED's surufat...
![](https://cdn.snapi.dev/images/v1/d/8/press17-2428463.jpg)
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrat...
![](https://cdn.snapi.dev/images/v1/c/l/press13-2417232.jpg)
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that Dr Renu Bh...
![](https://cdn.snapi.dev/images/v1/h/b/press4-2394062.jpg)
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade —
![](https://cdn.snapi.dev/images/v1/s/4/press3-2358004.jpg)
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from ...
![](https://cdn.snapi.dev/images/v1/p/r/press8-2351931.jpg)
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
ROCKVILLE, Md. and SUZHOU, China , April 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial...
![](https://cdn.snapi.dev/images/v1/a/j/press20-2351212.jpg)
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 —